Regulation of cytokine-induced prostanoid and nitric oxide synthesis by extracellular signalregulated kinase 1/2 in lung epithelial cells

Experimental Lung Research

Volumn 36, Issue 9, 2010, Pages 558-571

  Rice, Pamela L ^a,b,c   Barrett, Bradley S ^c,d   Fritz, Jason M ^c,d   Srebernak, Mary C ^c,d   Kisley, Lori R ^c,d   Malkinson, Alvin M ^c,d   Dwyer Nield, Lori D ^c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Clara cells; IFN ; inflammation; lung; TNF

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CYCLIN D1; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; PROSTACYCLIN; PROSTAGLANDIN E2; PROSTANOID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; LUNG ALVEOLUS EPITHELIUM; LUNG TUMOR; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BUTADIENES; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; INTERFERON-GAMMA; LUNG; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; NITRIC OXIDE; NITRILES; PHOSPHORYLATION; PROSTAGLANDINS; RESPIRATORY MUCOSA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957996861     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902148.2010.491891     Document Type: Article

References (62)

1. Wu AH, Fontham ET, Reynolds P, Greenberg RS, Buffer P, Liff J, Boyd P, Henderson BE, Correa P: Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol. 1995;141:1023-1032.
2. Cohen BH, Diamond EL, Graves CG, Kreiss P, Levy DA, Menkes HA, Permutt S, Quaskey S, Tockman MS: A common familial component in lung cancer and chronic obstructive pulmonary disease. Lancet. 1977;2:523-526.
3. Duperron C, Castonguay A: Chemopreventive effcacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Car-cinogenesis. 1997;18:1001-1006.
4. Keith RL, Miller YE, Hoshikawa Y, Moore MD, Gesell TL, Gao B, Malkinson AM, Golpon HA, Nemenoff RA, Geraci MW: Manipulation of pulmonary prostacyclin syn-thase expression prevents murine lung cancer. Cancer Res. 2002;62:734-740.
5. Keith RL, Miller YE, Hudish TM, Girod CE, Sotto-Santiago S, Franklin WA, Nemenoff RA, March TH, Nana-Sinkam SP, Geraci MW: Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res. 2004;64:5897-5904.
6. Kisley LR, Barrett BS, Bauer AK, Dwyer-Nield LD, Barthel B, Meyer AM, Thompson DC, Malkinson AM: Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumori-genesis. Cancer Res. 2002;62:6850-6856.
7. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
8. Fujimoto H, Ando Y, Yamashita T, Terazaki H, Tanaka Y, Sasaki J, Matsumoto M, Suga M, Ando M: Nitric oxide synthase activity in human lung cancer. Jpn J Cancer Res. 1997;88:1190-1198.
9. Liu CY, Wang CH, Chen TC, Lin HC, Yu CT, Kuo HP: Increased level of exhaled nitric oxide and up-regulation of in-ducible nitric oxide synthase in patients with primary lung cancer. Br J Cancer. 1998;78:534-541.
10. Singh RP, Deep G, Chittezhath M, Kaur M, Dwyer-Nield LD, Malkinson AM, Agarwal R: Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst. 2006;98:846-855.
11. Tyagi A, Singh RP, Ramasamy K, Raina K, Redente EF, Dwyer-Nield LD, Radcliffe RA, Malkinson AM, Agarwal R: Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res. 2009;2:74-83.
12. Castelao JE, Bart RD, III, DiPerna CA, Sievers EM, Brem-ner RM: Lung cancer and cyclooxygenase-2. Ann Thorac Surg. 2003;76:1327-1335.
13. Bauer AK, Dwyer-Nield LD, Malkinson AM: High cyclooxy-genase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors. Carcinogenesis. 2000;21:543-550.
14. Muscat JE, Chen SQ, Richie JP, Jr., Altorki NK, Citron M, Olson S, Neugut AI, Stellman SD: Risk of lung carcinoma among users of nonsteroidal antiinfammatory drugs. Cancer. 2003;97:1732-1736.
15. Moody TW, Leyton J, Zakowicz H, Hida T, Kang Y, Jakowlew S, You L, Ozbun L, Zia H, Youngberg J, Malkinson A: In-domethacin reduces lung adenoma number in A/J mice. Anti-cancer Res. 2001;21:1749-1755.
16. Rioux N, Castonguay A: Prevention of NNK-induced lung tu-morigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res. 1998;58:5354-5360.
17. 2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specifc PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem. 2004;334:266-275.
18. Nana-Sinkam P, Golpon H, Keith RL, Oyer RJ, Sotto-Santiago S, Moore MD, Franklin W, Nemenoff RA, Geraci MW: Prostacyclin in human non-small cell lung cancers. Chest. 2004;125:141S.
19. Dwyer-Nield LD, Srebernak MC, Barrett BS, Ahn J, Cosper P, Meyer AM, Kisley LR, Bauer AK, Thompson DC, Malkin-son AM: Cytokines differentially regulate the synthesis of prostanoid and nitric oxide mediators in tumorigenic vs. non-tumorigenic mouse lung epithelial cell lines. Carcinogenesis. 2005;26:1196-1206.
20. Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA Jr, Johnson GL, Hirsch FR, Merrick DT, Franklin WA, Baron AE, Keith RL, Nemenoff RA, Malkinson AM, Geraci MW: Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol. 2005;167:1763-1775.
21. Nemenoff R, Meyer AM, Hudish TM, Mozer AB, Snee A, Narumiya S, Stearman RS, Winn RA, Weiser-Evans M, Geraci MW, Keith RL: Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor gamma. Cancer Prev Res (Phila Pa). 2008;1:349-356.
22. Gupta RA, Dubois RN: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001;1:11-21.
23. Belvisi MG, Saunders MA, Haddad EL, Hirst SJ, Yacoub MH, Barnes PJ, Mitchell JA: Induction of cyclo-oxygenase-2 by cytokines in human cultured airway smooth muscle cells: novel infammatory role of this cell type. Br J Pharmacol. 1997;120:910-916.
24. Barnes PJ: Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine Growth Factor Rev. 2003;14:511-522.
25. Robbins RA, Springall DR, Warren JB, Kwon OJ, Buttery LD, Wilson AJ, Adcock IM, Riveros-Moreno V, Moncada S, Polak J: Inducible nitric oxide synthase is increased in murine lung epithelial cells by cytokine stimulation. Biochem Biophys Res Commun. 1994;198:835-843.
26. Thompson DC, Porter SE, Bauer AK, Das KC, Ou B, Dwyer-Nield L, White CW, Malkinson AM: Cytokine-induced nitric oxide formation in normal but not in neoplastic murine lung epithelial cell lines. Am J Physiol. 1998;274:L922-L932.
27. Blackhall FH, Pintilie M, Michael M, Leighl N, Feld R, Tsao MS, Shepherd FA: Expression and prognostic signif-cance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res. 2003;9:2241-2247.
28. Mukohara T, Kudoh S, Yamauchi S, Kimura T, Yoshimura N, Kanazawa H, Hirata K, Wanibuchi H, Fukushima S, Inoue K, Yoshikawa J: Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer. 2003;41:123-130.
29. Vicent S, Lopez-Picazo JM, Toledo G, Lozano MD, Torre W, Garcia-Corchon C, Quero C, Soria JC, Martin-Algarra S, Manzano RG, Montuenga LM: ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer. 2004;90:1047-1052.
30. Malkinson AM, Dwyer-Nield LD, Rice PL, Dinsdale D: Mouse lung epithelial cell lines tools for the study of differentiation and the neoplastic phenotype. Toxicology. 1997;123:53-100.
31. Bentel JM, Lykke AW, Smith GJ: Cloned murine non-malignant, spontaneously transformed and chemical tumour-derived cell lines related to the type 2 pneumocyte. Cell Biol Int Rep. 1989;13:729-738.
32. Pan YH, Nuzum EO, Hanson LA, Beer DG: Ki-ras activation and expression in transformed mouse lung cell lines. Mol Car-cinog. 1990;3:279-286.
33. Brash AR, Jackson EK, Saggese CA, Lawson JA, Oates JA, FitzGerald GA: Metabolic disposition of prostacyclin in humans. J Pharmacol Exp Ther. 1983;226:78-87.
34. Malkinson AM, Miley FB, Chichester CH, Plopper CG: Isolation of nonciliated bronchiolar (Clara) epithelial cells from mouse lung. Methods Toxicol. 1993;1A:123-133.
35. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265-275.
36. Krishan A: Rapid fow cytofuorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol. 1975;66:188-193.
37. Rice PL, Goldberg RJ, Ray EC, Driggers LJ, Ahnen DJ: Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites. Cancer Res. 2001;61:1541-1547.
38. Dwyer-Nield LD, Dinsdale D, Cohen JJ, Squier MK, Malkin-son AM: Morphological assessment of apoptosis in human lung cells. Methods Mol Med. 2003;74:283-297.
39. Franklin CC, Srikanth S, Kraft AS: Conditional expression of mitogen-activated protein kinase phosphatase-1, MKP-1, is cy-toprotective against UV-induced apoptosis. Proc Natl Acad Sci \USA. 1998;95:3014-3019.
40. Davies SP, Reddy H, Caivano M, Cohen P: Specifcity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351:95-105.
41. Mamay CL, Schauer IE, Rice PL, Dwyer-Nield LD, You M, Sclafani RA, Malkinson AM: Cyclin D1 as a pro-liferative marker regulating retinoblastoma phosphorylation in mouse lung epithelial cells. Cancer Lett. 2001;168:165-172.
42. Meuwissen R, Berns A: Mouse models for human lung cancer. Genes Dev. 2005;19:643-664.
43. Zerbe LK, Dwyer-Nield LD, Fritz JM, Redente EF, Shroyer RJ, Conklin E, Kane S, Tucker C, Eckhardt SG, Gustafson DL, Iwata KK, Malkinson AM: Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. Cancer Chemother Pharmacol. 2008;62:605-620.
44. Ballaz S, Mulshine JL: The potential contributions of chronic infammation to lung carcinogenesis. Clin Lung Cancer. 2003;5:46-62.
45. Yao B, Zhang Y, Delikat S, Mathias S, Basu S, Kolesnick R: Phosphorylation of Raf by ceramide-activated protein kinase. Nature. 1995;378:307-310.
46. Hildt E, Oess S: Identifcation of Grb2 as a novel binding partner of tumor necrosis factor (TNF) receptor I. J Exp Med. 1999;189:1707-1714.
47. Stancato LF, Yu CR, Petricoin EF III, Larner AC: Activation of Raf-1 by interferon gamma and oncostatin M requires expression of the Stat1 transcription factor. J Biol Chem. 1998;273:18701-18704.
48. Sakatsume M, Stancato LF, David M, Silvennoinen O, Sahari-nen P, Pierce J, Larner AC, Finbloom DS: Interferon gamma activation of Raf-1 is Jak1-dependent and p21ras-independent. J Biol Chem. 1998;273:3021-3026.
49. Loewen GM, Tracy E, Blanchard F, Tan D, Yu J, Raza S, Mat-sui S, Baumann H: Transformation of human bronchial epithelial cells alters responsiveness to infammatory cytokines. BMC Cancer. 2005;5:145.
50. Asano K, Nakamura H, Lilly CM, Klagsbrun M, Drazen JM: Interferon gamma induces prostaglandin G/H synthase-2 through an autocrine loop via the epidermal growth factor receptor in human bronchial epithelial cells. J Clin Invest. 1997;99:1057-1063.
51. 2 to the nuclear envelope elicits topographically localized phospholipid hydrolysis. Biochem J. 1996;318(Pt 3):797-803.
52. Xie W, Herschman HR: Transcriptional regulation of prostaglandin synthase 2 gene expression by platelet-derived growthfactor and serum. J Biol Chem. 1996;271:31742-31748.
53. Kristof AS, Marks-Konczalik J, Moss J: Mitogen-activated protein kinases mediate activator protein-1-dependent human in-ducible nitric-oxide synthase promoter activation. J Biol Chem. 2001;276:8445-8452.
54. Hausel P, Latado H, Courjault-Gautier F, Felley-Bosco E: Src-mediated phosphorylation regulates subcellular distribution and activity of human inducible nitric oxide synthase. Oncogene. 2006;25:198-206.
55. Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, Cheever AW, Pearce EJ, Wynn TA: Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol. 2001;167:6533-6544.
56. Weinstein IB: Cancer. Addiction to oncogenes the Achilles heal of cancer. Science. 2002;297:63-64.
57. Hu Y, Bally M, Dragowska WH, Mayer L: Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apop-tosis. Mol Cancer Ther. 2003;2:641-649.
58. Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA: Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res. 2005;65:8423-8432.
59. Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R, McCubrey JA: Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway [review]. Int J Oncol. 2003;22:469-480.
60. Lu G, Liao J, Yang G, Reuhl KR, Hao X, Yang CS: Inhibition of adenoma progression to adenocarcinoma in a 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone-induced lung tumorigenesis model in A/J mice by tea polyphenols and caffeine. Cancer Res. 2006;66:11494-11501.
61. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upad-hyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, Garcia-Echeverria C, Weissleder R, Mahmood U, Cantley LC, Wong KK: Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008;14:1351-1356.
62. Sebolt-Leopold JS: Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein ki-nase pathway. Clin Cancer Res. 2008;14:3651-3656.